Cannabis for dementia agitation is not covered by health insurance, so families pay the full cost out of pocket. That cost now runs about $200 to $600 per month, while the strongest trial benefit comes from an investigational drug rather than a dispensary product. Agitation means restlessness, verbal aggression, or resisting care in late-stage dementia. THC is the part of cannabis that causes a high, CBD does not, and products sold today differ from the research formula in dose, purity, and oversight.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What did the latest trial actually test?
- Why does insurance not cover it?
- What will families pay?
- What should you verify first?
What did the latest trial actually test?
The NIH-funded LiBBY Phase II trial randomized 120 hospice-eligible dementia patients with agitation to purified oral THC plus CBD or placebo. Georgetown University School of Medicine reports agitation scores on the CMAI scale, a caregiver-rated measure of agitated behaviors, fell 10.61 points versus 4.35 points at two weeks with the active drug trial results. The tested product was an investigational oral drug called T2:C100, given through home or residence visits at 10 U.S.
medical centers. The University of Maryland program description states it was a research formulation, not commercial dispensary oil, gummies, or smoked cannabis. There are still no FDA-approved drugs for agitation at the end-of-life stage of dementia. Pennington Biomedical Research Center notes that gap is why the National Institute on Aging funded LiBBY.
Why does insurance not cover it?
Medicare, Medicaid, and private plans do not cover state-legal medical marijuana or non-approved CBD because federal law controls coverage and FDA approval is required. Dementia Care Central reports dispensary purchases also do not count toward Medicare Part B or Part D deductibles coverage rules. CMS also bars Medicare Advantage plans from offering medical marijuana or cannabis oil even as an extra supplemental benefit.
The reason is federal illegality, so a plan cannot reimburse it, accept receipts, or waive the rule for dementia. That leaves no prior authorization path to try. A doctor's recommendation does not make the purchase a covered medical claim.
What will families pay?
Patients and caregivers now pay out of pocket for dementia-related cannabis use. CannIntel places the monthly product cost at $200 to $600, depending on formulation and dose, plus state card, evaluation, and dispensing fees cost estimates.
Dose changes alter the monthly total fast. A higher twice-daily oil dose, a switch from capsules to oil, or a product change can move a family from the low end to the high end in one month.
What should you verify first?
Check FDA status before comparing products. The FDA states it has approved only Epidiolex for seizures plus Marinol, Syndros, and Cesamet for other narrow uses, with no cannabis or cannabinoid approved for dementia agitation FDA cannabis policy.
A dispensary label that suggests dementia calm, sleep, or behavior control does not equal the trial drug. Ask the prescribing clinician for a written plan that names the exact product, starting dose, dose limits, sedation and fall checks, and who to call if agitation worsens. Bring that product label and dose sheet to every care visit, because staff cannot judge safety from a strain name alone.
- Exact THC and CBD milligrams per dose and per day
- Total first-month cost, including card, visit, product, and renewal fees
- Coverage letter or denial, so the cost does not surprise a shared family budget
- Safety review with the dementia, hospice, or palliative team and pharmacist
